^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 expression

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    1d
    Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors (clinicaltrials.gov)
    P1, N=48, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    CCNE1 (Cyclin E1)
    |
    HER-2 amplification • HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • azenosertib (ZN-c3)
    2d
    Predictors of Response to Neoadjuvant Therapy in HER2-positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity. (PubMed, Mod Pathol)
    Higher HER2-HQE is associated with increased RCB. Quantifying HER2 heterogeneity via HQE and percentage of HER2 IHC 3+ may help optimize therapeutic strategies in clinical practice.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    2d
    Clinical characteristics and survival outcomes of young women with luminal HER2-low and HER2-ultralow breast cancer. (PubMed, Cancer Treat Res Commun)
    Approximately 40 % of young women with luminal HER2-negative breast cancers have HER2-low or ultralow disease. These findings highlight the importance of accurately assessing HER2 expression in YWBC to identify candidates for emerging HER2-targeted therapies such as trastuzumab deruxtecan.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    3d
    Impact of MET Gene Abnormalities on the Efficacy of Anti-HER2 Targeted Therapy in Chinese Gastric Cancer Patients: A Multicenter, Retrospective Cohort Study (ChiCTR2600117225)
    P=N/A, N=420, Not yet recruiting, Shanghai East Hospital; Shanghai East Hospital
    New trial
    |
    HER-2 expression
    3d
    This study aims to evaluate the efficacy and safety of Disitamab Vedotin combined with Cisplatin and Candelinib in the treatment of patients with locally advanced cervical cancer. (ChiCTR2500114983)
    P=N/A, N=30, Recruiting, Dalian Medical University Second Affiliated Hospital; Dalian Medical University Second Affiliated Hospital
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 expression
    |
    cisplatin • Aidixi (disitamab vedotin) • Kaitanni (cadonilimab)
    3d
    Trastuzumab rezetecan alone or in combination with adebrelimab in advanced solid tumors with HER2 expression or mutation: a prospective, multicenter, open, nonrandomized, multicohort study. (ChiCTR2500113763)
    P=N/A, N=200, Not yet recruiting, The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • HER-2 expression
    |
    Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    3d
    Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Low Advanced Breast Cancer and Brain Metastases: A Multicenter Retrospective Study (ChiCTR2500113697)
    P=N/A, N=46, Not yet recruiting, The Affiliated Hospital of Inner Mongolia Medical University; The Affiliated Hospital of Inner Mongolia Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression • HER-2 underexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    3d
    A prospective, single-arm, exploratory study of RC48 combination therapy in neoadjuvant treatment of HER2-expressing ovarian cancer (ChiCTR2600117491)
    P4, N=20, Not yet recruiting, Liaoning Cancer Hospital; Liaoning Cancer Hospital
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification • HER-2 expression
    |
    Avastin (bevacizumab) • carboplatin
    3d
    Disitamab Vedotin combining with Toripalimab versus adjuvant Toripalimab in HER2 expressed locally advanced UTUC patients after nephron-ureterectory: a prospective, multicentre, open-label, randomised, phase 3 trial (ChiCTR2500115471)
    P3, N=106, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)
    3d
    Disitamab Vedotin combining with Toripalimab versus adjuvant Toripalimab in HER2 expressed high-risk MIBC patients after radical cystectomy: a prospective, multicentre, open-label, randomised, phase 3 trial (ChiCTR2500111817)
    P3, N=128, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)
    3d
    A randomized, controlled, multicenter clinical study of SHR-A1811 in combination with bevacizumab for second-line treatment of metastatic colorectal cancer. (ChiCTR2600116782)
    P2, N=80, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
    |
    HER-2 overexpression • HER-2 expression
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • trastuzumab rezetecan (SHR-A1811) • leucovorin calcium
    3d
    Disitamab Vedotin and Adebrelimab in combination with SOX in the perioperative treatment of HER2-expressing Locally Advanced Esophageal Adenocarcinoma and Esophagogastric Junction Adenocarcinoma: A Prospective, Single-Arm Phase II Study (ChiCTR2500115516)
    P2, N=39, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    oxaliplatin • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)